Pediatric genitourinary tumors

Current Opinion in Oncology

Volumn 22, Issue 3, 2010, Pages 268-273

  McLean, Thomas W ^a   Buckley, Kevin S ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Childhood cancer; Genitourinary; Germ cell tumor; Rhabdomyosarcoma; Testicle; Wilms tumor

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FORKHEAD TRANSCRIPTION FACTOR; HYBRID PROTEIN; IFOSFAMIDE; INTEGRIN LINKED KINASE; IRINOTECAN; MICRORNA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX7; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; VINCRISTINE;

BONE DYSPLASIA; CHILDHOOD CANCER; CHROMOSOME 5Q; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE MUTATION; GENE TARGETING; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; GERM LINE; HUMAN; MOLECULAR BIOLOGY; MOLECULAR GENETICS; NEPHROBLASTOMA; NEPHRON SPARING SURGERY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHABDOMYOSARCOMA; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; TESTIS TUMOR; TREATMENT RESPONSE; TUMOR GENE; UROGENITAL TRACT CANCER; WTX GENE; X CHROMOSOME LINKED DISORDER;

CHILD; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; PROGNOSIS; UROGENITAL NEOPLASMS;

EID: 77951467568     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32833841a1     Document Type: Review

References (41)

1. Davidoff AM. Wilms' tumor. Curr Opin Pediatr 2009; 21:357-364.
2. Misch D, Steffen IG, Schonberger S, et al. Use of positron emission tomography for staging, preoperative response assessment and posttherapeutic evaluation in children with Wilms tumour. Eur J Nucl Med Mol Imaging 2008; 35:1642-1650.
3. D'Angio GJ. Pre or postoperative therapy for Wilms' tumor? J Clin Oncol 2008; 26:4055-4057.
4. Sredni ST, Gadd S, Huang CC, et al. Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical features. Clin Cancer Res 2009; 15:6800-6809.
5. Davidoff AM, Giel DW, Jones DP, etal. The feasibility and outcome of nephron-sparing surgery for children with bilateral Wilms tumor. The St Jude Children's Research Hospital experience: 1 999-2006. Cancer 2008; 112:2060-2070.
6. Spreafico F, Pritchard Jones K, Malogolowkin MH, et al. Treatment of relapsed Wilms tumors: lessons learned. Expert Rev Anticancer Ther 2009; 9:1 807-1815.
7. Malogolowkin M, Cotton CA, Green DM, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 2008; 50:236-241.
8. Dallorso S, Dini G, Faraci M, Spreafico F. SCT for Wilms' tumour. Bone Marrow Transplant 2008; 41 (Suppl 2):S128-S130.
9. Ruteshouser EC, Robinson SM, Huff V. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer 2008; 47:461-470.
10. Fukuzawa R, Anaka MR, Weeks RJ, et al. Canonical WNT signalling determines lineage specificity in Wilms tumour. Oncogene 2009; 28:1063-1075.
11. Corbin M, de Reynies A, Rickman DS, et al. WNT/beta-catenin pathway activation in Wilms tumors: a unifying mechanism with multiple entries? Genes Chromosomes Cancer 2009; 48:816-827.
12. Royer-Pokora B, Weirich A, Schumacher V, et al. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology. Cancer 2008; 113:1080-1089.
13. Scott RH, Douglas J, Baskcomb L, etal. Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor. Nat Genet 2008; 40:1329-1334.
14. Wegert J, Wittmann S, Leuschner I, etal. WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact. Genes Chromosomes Cancer 2009; 48:1102-1111.
15. Rivera MN, Kim WJ, Wells J, et al. The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity. Proc Natl Acad Sci USA 2009; 106:8338-8343.
16. Jenkins ZA, van Kogelenberg M, Morgan T, etal. Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nat Genet 2009; 41:95-100.
17. Dallosso AR, Hancock AL, Szemes M, et al. Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms' tumor. PLoS Genet 2009; 5:e1000745.
18. Fukuzawa R, Anaka MR, Heathcott RW, et al. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes. J Pathol 2008; 215:377-387.
19. Sebire NJ, Vujanic GM. Paediatric renal tumours: recent developments, new entities and pathological features. Histopathology 2009; 54:516-528.
20. Miniati D, Gay AN, Parks KV, et al. Imaging accuracy and incidence of Wilms' and non-Wilms' renal tumors in children. J Pediatr Surg 2008; 43:1301-1307.
21. Sausville JE, Hernandez DJ, Argani P, Gearhart JP. Pediatric renal cell carcinoma. J Pediatr Urol 2009; 5:308-314.
22. Hayes-Jordan A, Andrassy R. Rhabdomyosarcoma in children. Curr Opin Pediatr 2009; 21:373-378.
23. Loeb DM, Thornton K, Shokek O. Pediatric soft tissue sarcomas. Surg Clin North Am 2008; 88:615-627.
24. Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclopho sphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. J Clin Oncol 2009; 27:5182-5188.
25. Rodeberg DA, Stoner JA, Hayes-Jordan A, et al. Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 2009; 27:3705-3711.
26. Bisogno G, Ferrari A, Prete A, et al. Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma. Eur J Cancer 2009; 45:3035-3041.
27. Stiff PJ, Agovi MA, Antman KH, et al. High-dose chemotherapy with blood or bone marrow transplants for rhabdomyosarcoma. Biol Blood Marrow Transplant 2009. [Epub ahead of print]
28. Bersani F, Taulli R, Accornero P, et al. Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma. Eur J Cancer 2008; 44:876-884.
29. Davicioni E, Anderson MJ, Finckenstein FG, et al. Molecular classification of rhabdomyosarcoma: genotypic and phenotypic determinants of diagnosis-a report from the Children's Oncology Group. Am J Pathol 2009; 174:550-564.
30. Durbin AD, SomersGR, Forrester M, et al. JNK1 determines the oncogenic or tumor-suppressive activity of the integrin-linked kinase in human rhabdomyosarcoma. J Clin Invest 2009; 119:1558-1570.
31. Taulli R, Bersani F, Foglizzo V, et al. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest 2009; 119:2366-2378.
32. Taniguchi E, Nishijo K, McCleish AT, et al. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 2008; 27:6550-6560.
33. Naini S, Etheridge KT, Adam SJ, et al. Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. Cancer Res 2008; 68:9583-9588.
34. Ross JH. Prepubertal testicular tumors. Urology 2009; 74:94-99.
35. Carkaci S, Ozkan E, Lane D, Yang WT. Scrotal sonography revisited. J Clin Ultrasound 2010; 38:21-37.
36. Cao D, Li J, Guo CC, et al. SALL4 is a novel diagnostic marker for testicular germ cell tumors. Am J Surg Pathol 2009; 33:1065-1077.
37. Cotton CA, Peterson S, Norkool PA, et al. Early and late mortality after diagnosis of Wilms tumor. J Clin Oncol 2009; 27:1304-1309.
38. Taylor AJ, Winter DL, Pritchard-Jones K, et al. Second primary neoplasms in survivors of Wilms' tumour: a population-based cohort study from the British Childhood Cancer Survivor Study. Int J Cancer 2008; 122:2085-2093.
39. Han JW, Kwon SY, Won SC, et al. Comprehensive clinical follow-up of late effects in childhood cancer survivors shows the need for early and well timed intervention. Ann Oncol 2009; 20:1170-1177.
40. Zeltzer LK, RecklitisC, Buchbinder D, et al. Psychological status in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2009; 27:2396-2404.
41. Wright KD, Green DM, Daw NC. Late effects of treatment for Wilms tumor. Pediatr Hematol Oncol 2009; 26:407-413.